Research programme: bone disorder therapeutics - Enzo Therapeutics/University of ConneticutAlternative Names: Enzo D58; IIIC3
Latest Information Update: 30 Sep 2009
At a glance
- Originator Enzo Therapeutics; University of Connecticut
- Class Small molecules
- Mechanism of Action Osteogenesis stimulants; Signal transduction pathway modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bone disorders; Periodontal disorders